Pressure BioSciences, Inc. to Present at the 2017 Biotech Showcase
SOUTH EASTON, MA–(Marketwired – Jan 10, 2017) – Pressure BioSciences, Inc. (OTCQB: PBIO)
(“PBI” and the “Company”), a leader in the development and sale of
broadly enabling, pressure cycling technology (“PCT”)-based sample
preparation solutions to the worldwide life sciences industry, today
announced that Mr. Richard T. Schumacher, President and CEO, will
present a corporate overview at the 9th Annual Biotech
Showcase at 5pm PST on Tuesday, January 10, 2017. The Biotech Showcase
is being held January 9-11, 2017 at the Hilton San Francisco Union
Square, San Francisco, CA.
About Biotech Showcase
Biotech Showcase™ is an investor and partnering conference
devoted to providing private and public biotechnology and life sciences
companies with an opportunity to present to, and meet with, investors
and pharmaceutical executives in one place during the course of one of
the industry’s largest annual healthcare investor conferences. Investors
and biopharmaceutical executives from around the world gather in San
Francisco during this critical week which is widely viewed as setting
the tone for the coming year. Now in its ninth year, this rapidly
growing conference features multiple tracks of presenting companies,
plenary sessions, workshops, networking, and an opportunity to schedule
one-to-one meetings. In addition to biopharmaceutical and life science
company executives, Biotech Showcase delegates include investors in
private and public companies, sector analysts, bankers and industry
professionals.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO)
develops, markets, and sells proprietary laboratory instrumentation and
associated consumables to the estimated $6 billion life sciences sample
preparation market. Our products are based on the unique properties of
both constant (i.e., static) and alternating (i.e., pressure cycling
technology, or PCT) hydrostatic pressure. PCT is a patented enabling
technology platform that uses alternating cycles of hydrostatic pressure
between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions. To date, we have installed nearly
300 PCT systems in approximately 160 sites worldwide. There are over 100
publications citing the advantages of the PCT platform over competitive
methods, many from key opinion leaders. Our primary development and
sales efforts are in the biomarker discovery, drug discovery and design,
and forensics areas. Customers also use our products in other areas,
such as bio-therapeutics characterization, soil & plant biology,
vaccine development, and counter-bioterror applications.
For more information about PBI and this press release, please click on the following link: http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.
Contact Information
Investor Contacts:
Richard T. Schumacher
President & CEO
(T) 508-230-1828
Jeffrey N. Peterson
Chairman
(T) 650 812-8121
In the interest of full disclosure, we call the reader’s
attention to the fact that Equities.com, Inc. is compensated by the
companies profiled in the Spotlight Companies section. The purpose of
these profiles is to provide awareness of these companies to investors
in the micro, small-cap and growth equity community and should not in
any way be considered as a recommendation to buy, sell or hold these
securities. Equities.com is not a registered broker dealer, investment
advisor, financial analyst, investment banker or other investment
professional. We are a publisher of original and third party news and
information. All profiles are based on information that is available to
the public. The information contained herein should not be considered to
be complete and is not guaranteed by Equities.com to be free from
misstatement or errors. The views expressed are our own and not intended
to be the basis for any investment decision. Readers are reminded to do
their own due diligence when researching any companies mentioned on
this website. Always bear in mind that investing in early-stage
companies is risky and you are encouraged to only invest an amount that
you can afford to lose completely without any change in your lifestyle.
Equities has been compensated with cash, common shares and/or warrants
for market awareness services provided.
Read Next
